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Summary: Rats given a single toxic dose of cisplatin all developed detectable glutathione-S-transferase
activity in their urine between the third and fifth day after injection of cisplatin, simultaneously with the
decreased urine osmplality and increased urine volume characteristic of cisplatin nephrotoxicity. Peak urinary
glutathione-S-transferase levels occurred at the same time äs maximal serum creatinine levels, and there was
a significant statisticäl correlation between these two variables. These findings suggest that urinary gluta-
thione-S-transferase activity is a marker for proximal renal tubular injury from cisplatin.
Nephrotoxizität von Cisplatin bei der Ratte: Ausscheidung von Glutathion-S-transferase im Harn
Zusammenfassung: Ratten erhielten eine toxische Einzeldosis von Cisplatin. Alle Tiere entwickelten zwischen
dem dritten und dem fünften Tag nach Injektion von Cisplatin eine nachweisbare katalytische Aktivität von
Glutathion-S-transferase im Harn. Zugleich trat die für die Nephrotoxizität von Cisplatin charakteristische
Zunahme des Harnvolumens und Abnahme der Osmolalität des Harns auf. Die höchste katalytische Aktivität
von Glutathion-S-transferase im Harn fand sich gleichzeitig mit der höchsten Konzentration von Kreatinin
im Serum. Es bestand eine signifikante statistische Korrelation zwischen diesen beiden Variablen. Unsere
Ergebnisse weisen darauf hin* daß die katalytische Aktivität von Glutathion-S-transferase im Harn ein
Merkmal für eine Schädigung des proximalen Nierentubulus durch Cisplatin ist.
Introduction proximal tubular injury. This enzyme is abundant in
the cytosol of proximal renal tubular cells, äs well äs
Cisplatin is a widely used antmeoplastic drug whose ^ h tocytes and small intestinal mucosa (8). In
major toxic effect is on the kidney. The drug causes ^^ tQ w a general binding protein fm Qr_
necrosis of proximal tubular cells both m patients (l, ganjc ^Q^ steroidSj and carcinogens (9)> it cata.
2) and experimental animals (3, 4). This lesion is ^ conjugation of certain Ugands to the sulfhy-
frequently associated with renal failure, wtoch is par- ^ rQ of reduced glutathione (10). Qlutathione-
tially anieliorated by pretreatment with intravenous s.tratlsferase is not found in the urine of normai
Huids and osmqüc dmretics (5). vom*]» or humans (6, 7, 11). In this study we mea-
Previous studies using other nephrotoxic substances, sured urine glutathione-S-transferase during exper-
such äs heavy metals (6) and gentamicin (7), have imental cisplatin nephrotoxicity, äs we feit that this
shown that the appearance pf glutathione-S-transfer- substance might indicate tubular damage, äs it does
äse B (ligandin) in the urine is a good marker for in other models.
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Materials and Methode
All studies were performed on male Sprague-Dawley rats weigh-
ing 200—300g. Eight animals were placed in metal metabolic
cages that separated urine from feces and were given 20g of
food (Charles River Mouse and Hamster formula chow) and
100 ml of tap water daily. After the rats consistently ate all
their food and established a constant drinking pattern (a period
usually lasting 5-7 days), cisplatin, 5mg/kg (lg/1 in 154
mmol/1 NaCl), was administered intraperitoneally. The con-
sumption of food and water and the excretion of urine, collected
under oil in plastic graduated cylinders, was determined daily,
beginning one day prior to cisplatin injection, so that each rat
served s its own control. Blood for creatinine determination
was drawn into heparinized tuberculin syringes by cardiac
puncture on the day of cisplatin administration and on the
fourth and seventh day thereafter.
Urine osmolality was measured by a vapor pressure osmometer
(Wescor, Inc., Logan UT, USA, Model 5100 C). Plasma crea-
tinine was determined by kinetic analysis of the chromogen
formed by creatinine upon reaction with picric acid (Technicon
Autoanalyzer).
Glutathione-S-transferase activity was determined quantita-
tively by measuring the rate of enzyme-catalyzed conjugation
of reduced glutathione with l-chloro-2,4-dinitrobenzene (7).
Two hundred microliters of urine was added to 2.5 ml of a test
solution containing l mmol/1 l-chloro-2,4-dinitrobenzene and
l mmol/1 reduced glutathione (both from Sigma Chemical Co.,
St. Louis, MO, USA) in 0.1 mol/1 potassium phosphate buffer
at pH 6.5. Enzyme activity was measured s a function of
absorbance at a wavelength of 344 nm in a Spectronic 2000®
dual beam recording spectrophotometer (Bausch & Lomb,
Rochester, NY, USA). A control solution containing all re-
agents without the urine was run simultaneously to allow the
automatic subtraction of noncatalyzed conjugation. Activity
was expressed s micromol of glutathionedinitrobenzene conju-
gate per minute. Twenty-four-hour urine gluthatione-S-trans-
ferase excretion was determined by multiplying the value ob-
tained from each aliquot by 5 and then by the urine volume in
ml.
The excretion of cisplatin in the urine of rats is inconsequential
by 24 hours following injection of the drug (12, 13). However,
to rule out any effect of urinary cisplatin on the enzymatic
reaction, the reaction was measured on a solution containing
1.1 mmol/1 cisplatin, l mmol/1 glutathione and l mmol/1
l-chloro-2,4-dinitrobenzene in the buffer, and a Standard quan-
tity of glutathione-S-transferase. This was compared with the
reaction of an identical solution without the cisplatin.
Serial results were compared statistically with the baseline using
Studenfs t-test for paired data. Linear regression was deter-
mined by the method of least squares.
Results
Each of the rats developed a substantial decrease in
renal function by the fourth day after injection of
cisplatin, s documented by a 60 — 267% increase in
plasma creatinine above pre-injection levels. The
mean control creatinine level was 33 ± 3 μιηοΐ/ΐ (0.38
± 0.03 mg/dl); by day 4 this had risen to 81 ± 6
μιηοΐ/ΐ (0.91 ± 0.07 mg/dl). As noted in figure l,
there was a concomitant fall in urine osmolality.
Urine volume was increased by day 4.
Urinary glutathione-S-transferase was undetectable
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Fig. 1. Plasma creatinine eoncentration, urine osmolality, and
urine glutathione-S-transferase activity in rats given an
injection of cisplatin at the beginning of day 1.
appear after the third day post injection of cisplatin
(tab. 1). By the fifth day, all animals had detectable
glutathione-S-transferase in their urine, with a mean
of 0.77 ± 0.11 nmol/min - 200 μΐ aliquot.
The enzymuria decreased during the sixth and sev-
enth days: all of the rats had absent or markedly
lower urinary glutathione-S-transferase levels during
the final 24-hour collection period. The peak enzym-
uria preceded by l — 2 days the nadir of urine osmo-
lality and maximum urine volume (fig. 1).
Twenty-four-hour urinary glutathione-S-transferase
excretion rose from zero in all animals to become
maximal between the fourth and fifth days post cis-
platin injection. This ranged from 42.3 to 246 nmol/
min - 24 h at day 4—5, with a mean of 115.8 ± 20.7.
There was a modest correlation between maximum
24-hour urinary glutathione-S-transferase and peak
plasma creatinine, with r = 0.73 (p < 0.05). Addition
of 1.1 mmol/1 cisplatin to a known solution of glu-
tathione-S-traiisferase did not affect its enzymatic
activity compared to a control.
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Discussion
Within four to five days following injection of a
nephrotoxic dose of cisplatin, all animals in this series
developed detectable levels of glutathione-S-transfer-
ase in their urine. This was associated with the pre-
viously described manifestations of cisplatin-induced
acute renal failure: elevated plasma creatinine, in-
creased urine volume and decreased urine osmolality
(4). By the seventh day after injection, urinary enzyme
activity was markedly diminished (tab. 1).
This pattern of urinary glutathione-S-transferase ex-
cretion is similar to that found in rats given other
proximal tubular toxins: absence in the control pe-
riod, appearance of enzymuria after administration
of the toxin, and finally disappearance of detectable
urinary glutathione-S-transferase following peak ex-
cretion (6). The period of enzymuria following cispla-
tin administration appears to last approximately 48
to 72 hours, äs it does in mercury and dichromate
toxicity (6,11).
Glutathione-S-transferase is normally undetectable in
urine except by radioimmunoassay for the enzymatic
protein (i. e. ligandin) (14). When there is proximal
tubular necrosis, the enzyme is released into the uri-
nary space and washed into the urine (11). It might
also appear in the blood at this point and could enter
the urinary space via filtration, although its molecular
weight (M = 44000) might impede passage across
the glomerular capillary barrier.
The morphological changes in tubular cells following
a toxic dose of cisplatin occur after 72 hours (4, 15).
In this study, glutathione-S-transferase appeared in
the urine between 72 and 96 hours after cisplatin.
This suggests that tubular cell disruption occurs at
this time. This coincided with the disturbances in
glomerular filtration rate (äs determined from the
rise in serum creatinine) and tubular function (äs
determined by low urine osmolality) (fig. 1). The
correlation between peak serum creatinine and max-
imum urine glutathione-S-transferase excretion im-
plies that the amount of this cytosolic protein released
into the urine may reflect the degree of tubular injury.
Earlier studies of urinary glutathione-S-transferase in
nephrotoxic renal injury also found enzymuria at the
time of cellular injury (6, 7). A recent investigation
of cadmiuin nephrotoxicity found that urinary glu-
tathione-S-transferase becomes elevated 13 weeks
after administration of the toxin: the time when cellu-
lar injury occurs (16). This confirms that urinary
glutathione-S-transferase is a useful prospective
marker of injury to the proximal nephron.
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